Two renowned metabolic clinical research companies – one focused on preclinical research and discovery, the other on translational clinical research – join forces to validate novel compounds for diabetes, obesity and NAFLD/NASH
SAN DIEGO, June 4, 2015 /PRNewswire/ – ProSciento Inc., an clinical research organization (CRO) focused on diabetes, obesity and NAFLD/NASH, announced today a strategic collaboration with Gubra ApS, a metabolic preclinical and drug discovery company, to combine expertise and resources to discover and translate into clinical research novel drug targets, compounds and biomarkers addressing metabolic disease.
According to the terms of the collaboration, Gubra will provide metabolic drug discovery expertise and pre-clinical target validation, as well as preclinical services, including in vivo pharmacology, histology and stereology, molecular biology, and assay development. ProSciento will provide early phase clinical services, regulatory management, and execution of clinical studies based on compound specific target product profiling and clinical development planning.
Both companies are members of the ProSciento founded Metabolic Research Partners™ network, an alliance of science and quality driven metabolism focused services providers to the biopharmaceutical and venture capital industries.
”We are delighted at the prospect of working with ProSciento, bringing together their clinical development and regulatory planning expertise with Gubra´s preclinical skills and know-how”, said Dr. Niels Vrang, Gubra CEO. “Not only is the complementarity between our companies nearly perfect, but we also find that the physical bridging of US and Europe biotech companies in collaborations like this has the potential to unlock ideas and opportunities that either company could not do by themselves. Additionally, for Gubra this collaboration not only consolidates the development of our early drug discovery candidates, but has the potential to boost our current target discovery programs in CNS obesity and NASH/NAFLD.”
“Gubra and ProSciento are two leading science driven organizations, solely focused on metabolism, addressing adjacent stages of the drug development process. Individually, the two companies have unrivaled expertise and experience in their specific stages of metabolic research and development,” said Dr. Marcus Hompesch, ProSciento CEO. “Together, we will contribute to highly efficient and effective metabolic drug development through meaningful science, advanced methodologies, and a combined team of experts.”
About Gubra ApS
Gubra is a privately-held biotech company in Hørsholm, Denmark. Gubra’s focus is diabetes, obesity, and related metabolic disorders. Within these core areas, Gubra delivers preclinical in vivo, in vitro and histology services to their partners. In addition to the CRO services, Gubra has several active early target, biomarker and peptide discovery programs. For more information, visit www.gubra.dk.
About ProSciento, Inc.
ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the global development of novel therapeutics for diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all metabolic drug and device classes. Utilizing its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, an unparalleled methodological tool kit, and operational execution from late preclinical to phase III readiness – ProSciento provides highly customizable services for its global client base in today’s rapidly evolving landscape of metabolic drug and device development. For more information, please visit www.prosciento.com.
For media inquiries, please contact:
Senior Director, Corporate Communications, ProSciento, Inc.
Tel: +1 858 663-6148
For business development inquires:
For clinical study enrollment inquires:
Tel: +1 (866) 308-7427
+45 3152 2651